Vericel (VCEL)
(Delayed Data from NSDQ)
$51.65 USD
+0.10 (0.19%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $51.70 +0.05 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.65 USD
+0.10 (0.19%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $51.70 +0.05 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
What Makes Vericel (VCEL) a New Strong Buy Stock
by Zacks Equity Research
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vericel (VCEL) delivered earnings and revenue surprises of 0% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -61.68% and 1,534%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice
by Zacks Equity Research
Does Vericel Corporation (VCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
by Zacks Equity Research
Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Vericel Corporation (VCEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.69% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Ideas feature highlights: Fresenius Medical Care, Vericel and ImmunoGen
by Zacks Equity Research
Fresenius Medical Care, Vericel and ImmunoGen are part of the Zacks Investment Ideas article.
Top Medical Stocks to Buy Amid Recent Market Volatility
by Shaun Pruitt
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
New Strong Buy Stocks for October 23rd
by Zacks Equity Research
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
New Strong Buy Stocks for October 19th
by Zacks Equity Research
INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.
Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 15.38% and 7.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 24.44% and 32.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.